...
首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
【24h】

Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.

机译:含替诺福韦二甲酚富马酸酯的高活性抗逆转录病毒治疗方案引起的肾功能不全的发生更为常见:一项队列研究和病例对照研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Tenofovir disoproxil fumarate (tenofovir DF), the first nucleotide analogue reverse transcriptase inhibitor approved for the treatment of HIV infection, has been associated with renal dysfunction in isolated cases. We investigated the overall incidence and risk of renal dysfunction in individuals receiving tenofovir DF and compared this with other antiretrovirals. METHODS: Data from the Chelsea and Westminster cohort were analyzed to reveal HIV-positive individuals with a creatinine value greater than 120 micromol/L at any time, the upper limit of normal used by our reference laboratory. These individuals were classified according to antiretroviral exposure and time exposed. A matched case-control study was performed comparing patients who had received tenofovir DF and subsequently developed a creatinine value greater than 120 micromol/L against controls who had been treated with tenofovir DF and had not experienced a creatinine elevation. RESULTS: Of 4183 HIV-positive patients, 1175 were identified as having a recorded creatinine value >120 micromol/L. Comparison of antiretroviral-naive patients and patients exposed to tenofovir DF- and non-tenofovir DF-containing regimens revealed a lower rate ratio and probability of developing a creatinine value >120 micromol/L in patients exposed to tenofovir DF (rate ratio vs. no antiretrovirals = 0.22, 95% confidence interval [CI]: 0.07-0.69; P < 0.001) with no significant difference between HAART regimens, corrected for duration of exposure. Of the 1058 individuals who were exposed to tenofovir DF, 84 (8%) patients experienced a creatinine value >120 micromol/L subsequent to exposure. An alternative etiology of renal dysfunction was found in 75 (90%) of these individuals. CONCLUSIONS: Tenofovir DF is not associated with renal dysfunction more frequently than other antiretroviral drugs, and the occurrence of renal dysfunction in this context is usually attributable to other causes.
机译:背景:替诺福韦二富马酸富马酸替诺福韦(tenofovir DF)是第一种被批准用于治疗HIV感染的核苷酸类似物逆转录酶抑制剂,与个别病例的肾功能不全相关。我们调查了接受替诺福韦DF的个体的总体发生率和肾功能不全的风险,并将其与其他抗逆转录病毒药物进行了比较。方法:对切尔西和威斯敏斯特研究小组的数据进行分析,以揭示在任何时候,肌酐值均大于120微摩尔/升的HIV阳性个体,这是我们参考实验室使用的正常上限。根据抗逆转录病毒暴露和暴露时间对这些人进行分类。进行了匹配的病例对照研究,比较了接受替诺福韦DF并随后肌酐值大于120 micromol / L的患者与接受替诺福韦DF治疗且未出现肌酐升高的对照。结果:在4183例HIV阳性患者中,有1175例被记录的肌酐值> 120 micromol / L。对未接受抗逆转录病毒治疗的患者与接受替诺福韦DF和不含替诺福韦DF的患者进行比较,发现暴露于替诺福韦DF的患者比率较低,肌酐值> 120 micromol / L的可能性更高(比率与无。抗逆转录病毒药= 0.22,95%置信区间[CI]:0.07-0.69; P <0.001),HAART方案之间无显着差异,已校正暴露时间。在暴露于替诺福韦DF的1058个人中,有84(8%)患者暴露后肌酐值> 120 micromol / L。在这些人中有75位(90%)发现了另一种肾功能不全的病因。结论:替诺福韦DF与其他抗逆转录病毒药物相比,与肾功能不全的相关性不高,在这种情况下肾功能不全的发生通常归因于其他原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号